View on market: Stay Cautious, be with quality business:

Asian stocks were mixed Wednesday after a megacap technology selloff weighed on U.S. equities. Japanese shares fluctuated, Australia climbed after a holiday break and South Korea declined. U.S. futures rose, suggesting the S&P 500 and the Nasdaq 100 might make up some ground after a dip Tuesday that snapped four sessions of gains. Volumes remained thin into the end of the year in some markets. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, fell 0.2% to 17,227.50, as of 7:10 a.m Treasuries and the dollar were little changed. Crude oil held an advance to the highest in more than a month. Bitcoin fell below $48,000. .

Economic Calendar:

  • INR: Foreign Exchange Reserve on 31st  December, 2021.
  • INR: Infrastructure Output YoY on 31st December 2021
  • USD: Goods Trade Balance on 29th December, 2021.
  • USD: API Weekly Crude Oil Stock on 29th December, 2021.

Brokerage Radar:

MORGAN STANLEY ON MACROTECH DEVELOPERS (Lodha): Initiate at Equalweight, Target Price Rs 1312 Plus, it is monetizing completed inventory, commercial assets & land bank earmarked for digital infrastructure projects Together, these provide good cash flow visibility, which should help in further deleveraging.

MORGAN STANLEY ON SBI CARDS: Overweight, Target Price of Rs 1350 after a strong Oct for industry (highest-ever spending, 26% MoM), spending moderated in Nov (-12% MoM), but was up 43% YoY SBIC spending moderated a slower 7% MoM (up 42% YoY) Cards in force for SBIC up 1.6% MoM, a tad lower than industry’s 1.8%.

NIRMAL BANG ON MUTHOOT FINANCE: Upgrade to Buy, Target Price Rs 1854 Recent correction offers good entry opportunity for investors Muthoot is expected to deliver EPS CAGR of 15% over FY21-24E over last 12-15 months, co has fortified its lead over competition.

KOTAK EQUITY ON TEAMLEASE: Upgrade to buy, Target Price Rs 4420 Company well positioned to see healthy increase in general staffing headcount as it improves its sales efforts in e-com & as core sectors recover PF trust deficit has been fully provided for.

International Markets:

U.S & Europe

Particulars 28th Dec Chg Chg(%)
Nasdaq 15,781.72 -89.54 -0.56
Dow 36398.21 95.83 0.26
FTSE 7,372.10 -1.24 -0.02
CAC 7,181.11 40.72 0.57
DAX 15,963.70 128.45 0.81
Dow Fut.* 36388.70 -9.50 -0.03

Asian markets:

Particulars 29th Dec Chg. Chg(%)
SGX Nifty 17,212.00 -50.5 -0.29
Nikkei 28,809.86 -259.3 -0.89
Straits Times 3,136.80 8.39 0.27
Hang Seng 23,115.12 -165.44 -0.71
Shanghai 3,615.09 -15.02 -0.41

ADR Watch:

Particulars 28th Dec Chg. Chg.(%)
Dr Reddy 63.56 -0.06 -0.09
HDFC Bank 64.14 0.13 0.2
ICICI Bank 19.54 0.05 0.26
Infosys 25.3 -0.03 -0.12
Tata Motor 31.72 -0.06 -0.19
Wipro 9.63 -0.01 -0.1

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 74.65 -0.34
Brent 78.73 -0.17
Gold 1807.70  -0.18
Silver 23.067 -0.23


Particulars 28th Dec 27th Dec
FIIs 207.31 -1038.25
DIIs 567.47 955.79

News Update:

Mahindra and Mahindra: M&M’s wholly-owned subsidiary, Mahindra Engineering and Chemical Products, has agreed to sell its entire stake aggregating to 49 percent of the paid-up equity share capital held in MahindraTsubaki Conveyor Systems.

Aurobindo Pharma: The Drugs Controller General of India’s granted permission to manufacture and market the company’s generic version of Molnupiravir, to be sold as Molnaflu, licensed from MSD and Ridgeback.

Dr Reddy’s Laboratories: The Company has received emergency-use authorisation from the Drugs Controller General of India to manufacture and market the oral anti-viral drug Molnupiravir capsules for the treatment of adult patients with COVID-19.

Natco Pharma: The Company received approval for the drug Molnupiravir, which will be sold under the brand name MOLNUNAT, for the treatment of Covid-19 in India.

Financial Services companies: RBI has warned that the impact of the pandemic is showing up in muted credit growth as banks remain largely risk-averse. The central bank has also warned that stress could rise and going ahead, the bank’s asset quality could get dented and it specifically warned that NBFC asset quality could see a further hit.

GR Infraprojects: The Company has emerged as an L-1 bidder for the tender invited by Noida Metro Rail Corporation. The order is for part design and construction of elevated viaduct and five elevated stations, of Noida-Greater Noida Metro Rail Project.

Mishtann Foods: The Company signed an agreement with the Gujarat Government for the proposed project of manufacturing grain-based ethanol in Gujarat.

GR Infraprojects: The Provisional Completion certificate has been issued by the Independent Engineer for the development of Purvanchal Expressway (Package-VII) from Mojrapur to Bijaura (Ghazipur) in Uttar Pradesh on EPC basis.

Vakrangee: The Company has announced a strategic tie-up with Nayara Energy. The company will set up Vakrangee Kendra outlets across the network of Nayara Energy and the tie-up will ramp up the physical network of Vakrangee Kendra outlets in urban and rural areas.

India Grid Trust: The consortium of IndiGrid 1 and IndiGrid 2, wholly-owned subsidiaries of India Grid Trust, has completed the acquisition of 100 percent paid-up capital and management control of Kallam Transmission.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL